Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02038569 · ClinicalTrials.gov registry record · Phase 2
An International, Multi-centre, Prospective, Non-controlled, Open, Single-group, 8-week Trial in Adolescent Subjects
A Phase 2 study, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
NCT02038569 is a Phase 2 study that has completed, run by LEO Pharma. The registered enrollment target is 125 participants.
The verdict
NCT02038569, a Phase 2 study, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
Study Summary
An international, multi-centre, prospective, non-controlled, open, single-group, 8-week trial in adolescent subjects (aged 12 to 16 years, 11 months) with scalp and body psoriasis.
Interventions
- DRUG LEO 80185 gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2014-01 |
| Est. Completion | 2018-02-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02038569
The ClinicalTrials.gov registry entry for NCT02038569 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LEO Pharma, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LEO 80185 gel is the first listed.
NCT02038569 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02038569 about?
NCT02038569 is a clinical study titled "An International, Multi-centre, Prospective, Non-controlled, Open, Single-group, 8-week Trial in Adolescent Subjects". An international, multi-centre, prospective, non-controlled, open, single-group, 8-week trial in adolescent subjects (aged 12 to 16 years, 11 months) with scalp and body psoriasis.
What is the current status of trial NCT02038569?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2014-01. Estimated completion is 2018-02-13.
What interventions are being tested in trial NCT02038569?
The interventions under investigation include: LEO 80185 gel (DRUG).
Who is sponsoring clinical trial NCT02038569?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.